Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

This study identified a mutation in the keratin 71 gene that causes curly hair in certain rats, advancing our understanding of hair formation.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This study investigated the role of NLRP3 inflammasomes in alopecia areata and found that outer root sheath cells may contribute to inflammation by increasing IL-1β and HMGB1 secretion when stimulated with double-stranded RNA.

This study observed that DMAP scaffolds in a full-thickness wound model promote dermal appendage regeneration by activating humoral immunity, specifically through B cell activation and antibody production, even when adaptive immune cells' infiltration is restricted.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

This thesis reviews current therapeutic approaches for ARFID and provides preliminary insights into enhancing treatment and care in Australia, including an evaluation of a pilot dietetic-led cognitive-behavioral therapy intervention.

In this study, carbon dots derived from metformin and dopamine (MD‐CDs) effectively promoted healing in bacterial-infected wounds by inhibiting infection, expediting inflammation-to-healing transition, enhancing cell proliferation and migration, and fostering collagen deposition and hair follicle regeneration.

This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.

In this study, researchers identified specific clinical and dermoscopic features of chronic radiation-induced dermatitis in 32 head and neck cancer patients treated with radiotherapy, and determined age, gender, and prior surgery as independent risk factors for developing this skin toxicity.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

This study identified a large deletion in the desmoglein 4 gene as the genetic basis of the Iffa Credo "hairless" rat's skin phenotype, linking it to lanceolate hair mutations.

This study observed that patients with rapidly progressive alopecia areata may have a favorable prognosis regardless of treatment, and regenerated vellus hairs were linked to higher improvement or cure rates.

This study developed a dissolvable microneedle system delivering specific molecules to remodel lymphatic networks and normalize metabolic processes, which accelerated hair growth and activated hair follicle stem cells in a mouse model of androgenetic alopecia.

This source describes alopecia as a hair loss condition often driven by genetic and androgenic factors, with lifestyle elements like chemical treatments exacerbating the issue; Ayurvedic texts caution against scalp toxins and suggest traditional formulations for support.

This narrative review reported that direct-to-consumer teledermatology improves access to care, adherence, and patient satisfaction for treating male androgenetic alopecia, but may lead to higher drug costs.

In this open-label trial, 9-cis-retinoic acid showed moderate activity against Kaposi sarcoma in AIDS patients, but its use is limited by substantial side effects at higher doses.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

In this study, peptide nanofiber gels RG and RJ significantly accelerated the healing of deep second-degree burn wounds in vivo, with greater wound closure rates and enhanced tissue regeneration compared to controls, attributed to increased angiogenesis and reduced systemic inflammation.

In this study, a new hairless gene in the Donryu rat strain was identified, showing skin similarities to human skin tumors with multiple follicular cysts.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.